This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another View: Looking at Momelotinib prior to the MOMENTUM readout in anemic myelofibrosis patients who have previously been on JAKi therapy

Ticker(s): SRRA

Who's the expert?

Institution: McGill (Jewish General Hospital)

  • Assistant Professor of Oncology at McGill.
  • Manages ~30 MF patients/month.
  • Established the first myeloproliferative neoplasms clinic in Canada; has authored several publications in the area of MPN clinical research and has been an investigator on several clinical trials assessing novel agents in the treatment of MPN.

Interview Questions
Q1.

Please describe your clinical practice and research relating to MF.

Added By: c_admin
Q2.

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Momelotinib?

Added By: c_admin
Q3.

What do you expect the Danazol arm to do on A) TSS B) TI C) SVR?

Added By: c_admin
Q4.

What do you expect the Momelotinib arm to do on A) TSS B) TI C) SVR?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.